* Please note that the following agenda timings are Eastern Standard Time.  


Coffee morning to meet your peers ahead of the conference

9:00 am Chair’s Opening Remarks

Driving Future Clinical Success

9:10 am Lessons Learned & Looking Beyond – Novartis’ Journey with TGF-β

9:40 am Panel Discussion: Realizing a Circular Approach to Enhance Clinical Success

10:20 am
Morning Networking Break


Meet and connect with your peers in this dedicated networking session

Preclinical Track

Overcoming the Complexity of TGF-β Pathways & Immune Cell Interactions

Chair: Divya Mathur, Director of Immuno-Oncology, Regeneron Pharmaceuticals

11:00 am Cancer Immunotherapy using TGF-β Conditioned Gamma Delta T-Cells

11:25 am Exploiting TGF-β Biology in Genotoxic Cancer Therapy

11:40 am Fireside Chat

Clinical Track

Defining Clinical Biomarkers to Maximize the Therapeutic Potential of TGF-β

11:00 am Development of a Comprehensive Biomarker Strategy to Support DRAGON, a Phase 1 Clinical Trial of SRK-181, the Latent TGFβ1 Inhibitor

11:30 am Determining the Promise of TGF-β With Chemotherapeutic Agents

  • Davide Melisi Associate Professor of Medical Oncology, University of Verona

12:00 pm Networking Lunch

Diving into the TGF-β Paradox in Immuno-Oncology

Chair: Divya Mathur, Director of Immuno-Oncology, Regeneron Pharmaceuticals

1:00 pm Discover the Potential of Integrin Inhibitors to Selectively Block TGF-β

  • Stephen Nishimura Professor & Chief of Pathology, University of California San Francisco

1:30 pm Exploring the Role of TGF-β in Regulating the Immune Environment

  • Mark Travis Head of Division of Infection, Immunity & Respiratory Medicine, University of Manchester

Evaluating Safety & Pharmacodynamics at Clinic

1:00 pm Safety Observations from Small Molecule Inhibitors of ALK5 in Patients

1:30 pm Validation of Surrogate FACS-Based Target Engagement Assay on Frozen Platelets to Evaluate Pharmacodynamic Effects in a Ph1 Dose Escalation Clinical Trial

2:00 pm
Afternoon Networking Break

Maximizing TGF-β’s Therapeutic Potential Beyond IO

2:30 pm A Novel IL-2-TGF-β Fusion Protein for Induction & Expansion of Regulatory T Cells for Autoimmune & Inflammatory Diseases

  • Anish Suri President & Chief Scientific Officer, Cue Bio

3:00 pm Harnessing the Parallels of TGF-β Drug Development in Fibrosis & Oncology

  • Nina Noskovicova Research Scientist, Maxwell Therapeutics at SBME Innovation Hub, University of British Columbia

3:30 pm Chair’s Closing Remarks

3:40 pm End of Day Two